The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review.
2001
Background
Type 2 diabetes mellitus is a chronic metabolic
disorder that results from defects in insulin
secretion and action. The resulting build-up of
glucose in the blood can cause a range of diabetic
complications, including macrovascular disease
(e.g. coronary, cerebral and peripheral vascular
disease) and microvascular disease (e.g. retinopathy,
nephropathy and neuropathies). People
with diabetes are at particularly high risk of
cardiovascular disease. This increased risk is
related, in part, to hyperglycaemia, and also
to hypertension and commonly associated
conditions such as adverse lipid profiles.
Evidence from the United Kingdom Prospective
Diabetes Study (UKPDS) has shown
that maintaining good control of blood glucose
reduces the incidence of diabetic complications.
It is thought that approximately 1 million
people in England and Wales suffer from
diabetes, the majority of whom suffer from
type 2 diabetes.
Clinical practice guidelines recommend a
‘step-up’ policy of treatment for type 2 diabetes,
starting with diet and lifestyle advice, adding
oral blood glucose-lowering agents (principally
metformin and the sulphonylureas) and eventually
using insulin, if targets are not achieved. Type 2
diabetes tends to be progressive, so therapies
may be initially effective but subsequently
control is lost. Pioglitazone is one of a new class
of oral glucose-lowering drugs, the peroxisome
proliferator-activated receptor-gamma agonists,
which also include rosiglitazone. These new
drugs have a mode of action that differs from
that of existing medications.
Objectives
This review was performed to evaluate the use of
pioglitazone in its licensed indication, in combination
with metformin or sulphonylurea. For
completeness, the review also considered its use
in combination with insulin and as monotherapy
(unlicensed indications).
Methods
A systematic review of the literature, involving
a range of databases, was performed to identify
all papers relating to pioglitazone, as well as
economic or model-based assessments focusing
on diabetes mellitus. Full details are described
in the main report.
Results
The results of unpublished company-sponsored
clinical trials were submitted in confidence to the
National Institute for Clinical Excellence (NICE)
by Takeda UK Ltd. Information from these studies
was included in the version of the report that was
sent to the Appraisals Committee, but is not
reported here.
Number and quality of studies
Fifteen studies met the inclusion criteria, but
full reports were available for only five. Of the
15 studies, nine dealt with pioglitazone alone
or in combination with a strict antidiabetic
diet. The remainder dealt with pioglitazone
in combination with metformin, insulin
or a sulphonylurea.
Clinical effectiveness
In both monotherapy and combination therapy,
pioglitazone appeared to be effective in reducing
blood glucose in patients with poorly controlled
type 2 diabetes. However, the US Food and
Drug Administration review observed that, when
pioglitazone was used as monotherapy, those
patients who were changed from another oral
antidiabetic agent (metformin or sulphonylurea)
to pioglitazone did not achieve the same level of
glycaemic control as they had previously experienced.
When used in combination with metformin,
sulphonylurea or insulin, pioglitazone led to a
significant fall in blood glucose and glycosylated
haemoglobin (HbA1C) at doses of 15 or 30 mg
daily, with a greater effect seen at the higher dose.
In addition, both monotherapy and combination
therapy studies have demonstrated a fall in triglyceride
levels and an increase in high-density
lipoprotein cholesterol levels when doses of
30 mg or more of pioglitazone were used.
Pioglitazone treatment is associated with
significant weight gain in the short term, which
appears to be greater than that seen with other
thiazolidinediones. This gain in weight also
appears to be greater than that seen in the
UKPDS with sulphonylurea or insulin treatment,
which in turn was greater than that seen with
metformin treatment. This weight gain continues,
albeit at a lesser rate, for more than a year.
Whether or not weight reaches a plateau after
this point cannot be stated with certainty
without longer-term follow-up.
There is no direct evidence available on the
effect of pioglitazone on diabetic complications,
including cardiovascular mortality. However,
as the UKPDS study has shown that improved
glycaemic control reduces the incidence of
microvascular complications, it would be
reasonable to expect that this beneficial effect
would hold true if a similar improvement in
metabolic control was achieved using pioglitazone.
Changes in lipid levels could be expected to lead
to a reduction in cardiovascular disease risk.
However, many studies found that treatment
was also associated with significant and progressive
weight gain, which would have an
adverse effect on the risk of coronary
artery disease.
There is also no direct evidence that, for patients
whose diabetes is poorly controlled by metformin
or sulphonylurea, the addition of pioglitazone is
any more effective in improving glycaemic control
than moving to a metformin–sulphonylurea
combination or starting insulin therapy.
Health economics
Takeda UK Ltd submitted data from a confidential
economic model to NICE. Information about this
study was included in the version of the report that
was sent to the Appraisals Committee, but cannot
be reported here.
Conclusions
The evidence suggests that, compared with
placebo, pioglitazone is effective in reducing
blood glucose in patients with inadequate
glycaemic control, both when used as monotherapy
and in combination with existing licensed
therapies. However, there is no firm evidence to
indicate that pioglitazone is more effective than
any other antidiabetic agent, particularly when
used in combination. Additionally, it is unclear
how pioglitazone therapy affects the incidence of
microvascular and cardiovascular complications.
Recommendations for research
Evidence is needed regarding:
1. the clinical effectiveness and cost-effectiveness of
pioglitazone in combination therapy compared
with other possible combination therapies (e.g.
rosiglitazone in combination, or sulphonylurea
plus metformin, or insulin with or without an
oral antidiabetic agent)
2. whether or not the risk of microvascular
complications is reduced by the improved
glycaemic control achieved using pioglitazone
3. whether or not the risk of cardiovascular events
is reduced by the changes in lipid levels
achieved using pioglitazone.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
19
Citations
NaN
KQI